Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

Expectations for both companies are really high. Morningstar estimates the GLP-1 drug market will be worth $200bn by 2031, and analysts expect Eli Lilly and Novo Nordisk to take the lion’s share of it ...

A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand ...

The average premium paid by companies for family coverage rose 7% for a second year in 2024, to $25,572 — without yet ...

While shares have posted break-even returns so far in 2024, Pfizer stock has cratered by more than 30% over the ...

Compounding pharmacies sued the FDA after its declaration, bringing an end to the sale of the "copycat" drugs they provide. Meanwhile, as demand soars for weight loss drugs, WeightWatchers eyes ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

(THE CONVERSATION) In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to ...

The U.S. hedge fund disclosed the stake in Gerresheimer in a regulatory filing published late Tuesday. Based on Gerresheimer's market capitalization of 2.69 billion euros ($2.95 billion) as of Tuesday ...

A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's ...